Warning Letter — Best Chinese Medicines LLC
The FDA issued a Warning Letter to Best Chinese Medicines LLC following a review of product claims that classify their items as unapproved new drugs. The Center for Drug Evaluation and Research (CDER) identified regulatory violations regarding how these products are marketed and distributed.
This affects Best Chinese Medicines LLC, its regulatory and quality compliance departments, and distributors of similar traditional or alternative medicinal products making health claims.
This action indicates that the FDA is actively monitoring online platforms for products marketed with therapeutic claims that bypass the drug approval process. For firms in the alternative medicine space, this highlights a significant risk if labeling or website copy suggests a product can mitigate or treat specific medical conditions, potentially leading to enforcement actions such as seizures or injunctions if not remediated.
Review all product listings and marketing materials to ensure no claims suggest the prevention, treatment, or cure of diseases. Implement a robust regulatory review process for third-party or imported product labeling to ensure compliance with FDA drug definitions.
FDA Warning Letter issued to: Best Chinese Medicines LLC. 10/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/best-chinese-medicines-llc-738556-10232026
Open in openFDA / FDA.gov